Cryo-Cell InternationalSTU:ZCY -2.52%58 EBITDA Margin % is 11.38% as of Feb. 2026, which is 37% below its 10-year median of 18.10. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €6.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 70.68% on this metric.
Cryo-Cell International (STU:ZCY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cryo-Cell International EBITDA Margin % Related Terms
Cryo-Cell International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs CCM, CDIX, EHSI: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a EBITDA Margin % of 11.38% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cryo-Cell International and its competitors. This is 37% below median its historical median of 18.10. According to the industry distribution chart, Cryo-Cell International ranks #470 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 70.7%.
Is Cryo-Cell International's EBITDA Margin % too high?
Cryo-Cell International's current EBITDA Margin % of 11.38% is 37% below median its 10-year median of 18.10. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Cryo-Cell International's value of 11.38% is 11.1% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #470 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's EBITDA Margin % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #470 out of 665 companies for EBITDA Margin %. This places Cryo-Cell International in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Cryo-Cell International's value of 11.38% is 11.1% above this benchmark. While the company's 10-year median is 18.10 vs. the industry median of 10.24, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current EBITDA Margin % of 11.38% is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current EBITDA Margin % is 11.38%, which is 37% below median its own 10-year median of 18.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €6.10, compared to a current price of €3.10 — trading 49.2% below its estimated fair value. The current EBITDA Margin % is 11.38%, which is 37% below median its 10-year median of 18.10 and 11.1% above the Healthcare Providers & Services industry median of 10.24. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current EBITDA Margin % is 11.38% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €3.10 is trading 49.2% below its estimated GF Value™ of €6.10.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
EBITDA Margin %: 11.38% (37% below median its 10-year median of 18.10)
GF Value™: €6.10 vs. price of €3.10 (49.2% below fair value)
Industry Position: 11.1% above the Healthcare Providers & Services median (#470 of 665)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
